A detailed history of 1620 Investment Advisors, Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 992 shares of PCRX stock, worth $25,246. This represents 0.01% of its overall portfolio holdings.

Number of Shares
992
Previous 1,027 3.41%
Holding current value
$25,246
Previous $15,000 20.0%
% of portfolio
0.01%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

SELL
$15.3 - $20.33 $535 - $711
-35 Reduced 3.41%
992 $18,000
Q3 2024

Oct 25, 2024

BUY
$11.7 - $28.46 $5,136 - $12,493
439 Added 74.66%
1,027 $15,000
Q2 2024

Jul 23, 2024

BUY
$25.5 - $31.51 $14,994 - $18,527
588 New
588 $16,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $1.17B
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track 1620 Investment Advisors, Inc. Portfolio

Follow 1620 Investment Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 1620 Investment Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on 1620 Investment Advisors, Inc. with notifications on news.